JP2024520788A - 経口利尿薬に不応性の浮腫を処置するための皮下製剤及び方法 - Google Patents

経口利尿薬に不応性の浮腫を処置するための皮下製剤及び方法 Download PDF

Info

Publication number
JP2024520788A
JP2024520788A JP2023575713A JP2023575713A JP2024520788A JP 2024520788 A JP2024520788 A JP 2024520788A JP 2023575713 A JP2023575713 A JP 2023575713A JP 2023575713 A JP2023575713 A JP 2023575713A JP 2024520788 A JP2024520788 A JP 2024520788A
Authority
JP
Japan
Prior art keywords
bumetanide
pharmaceutical composition
subject
aqueous solution
arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520788A5 (cg-RX-API-DMAC10.html
Inventor
ラダクリシュナン，バラシンガム
エスケ，ベン
リン，ウェイ
チェン，アンドリュー，シャン
Original Assignee
レスク ファーマシューティカルズ エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レスク ファーマシューティカルズ エルエルシー filed Critical レスク ファーマシューティカルズ エルエルシー
Publication of JP2024520788A publication Critical patent/JP2024520788A/ja
Publication of JP2024520788A5 publication Critical patent/JP2024520788A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
JP2023575713A 2021-06-09 2022-06-09 経口利尿薬に不応性の浮腫を処置するための皮下製剤及び方法 Pending JP2024520788A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163208863P 2021-06-09 2021-06-09
US63/208,863 2021-06-09
PCT/US2022/032862 WO2022261344A1 (en) 2021-06-09 2022-06-09 Subcutaneous formulation and methods for treating edema refractory to oral diuretics

Publications (2)

Publication Number Publication Date
JP2024520788A true JP2024520788A (ja) 2024-05-24
JP2024520788A5 JP2024520788A5 (cg-RX-API-DMAC10.html) 2025-06-16

Family

ID=84425561

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575713A Pending JP2024520788A (ja) 2021-06-09 2022-06-09 経口利尿薬に不応性の浮腫を処置するための皮下製剤及び方法

Country Status (10)

Country Link
US (1) US20240285566A1 (cg-RX-API-DMAC10.html)
EP (1) EP4351554A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024520788A (cg-RX-API-DMAC10.html)
KR (1) KR20240042402A (cg-RX-API-DMAC10.html)
CN (1) CN117915905A (cg-RX-API-DMAC10.html)
AU (1) AU2022289724A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023025880A2 (cg-RX-API-DMAC10.html)
CA (1) CA3221710A1 (cg-RX-API-DMAC10.html)
IL (1) IL309160A (cg-RX-API-DMAC10.html)
WO (1) WO2022261344A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3160278A1 (en) 2019-12-04 2021-06-10 Balasingam Radhakrishnan Methods and compositions for treating edema refractory to oral diuretics

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539995A (ja) * 2006-06-16 2009-11-19 ノヴァカーディア，インク． うっ血性心不全および急性体液過剰の患者において入院期間を短縮するための方法
JP2016515623A (ja) * 2013-04-05 2016-05-30 エスシーファーマシューティカルズ インコーポレイテッド フロセミドの皮下投与用の医薬製剤
JP2023505189A (ja) * 2019-12-04 2023-02-08 レスク ファーマシューティカルズ エルエルシー 経口利尿薬に不応性の浮腫を処置するための方法及び組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040105818A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
EP2086329B1 (en) * 2006-10-26 2014-07-23 The Arizona Board of Regents on behalf of the University of Arizona Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
US20140128469A1 (en) * 2011-05-10 2014-05-08 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
WO2019193161A1 (en) * 2018-04-06 2019-10-10 Universität Wien Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539995A (ja) * 2006-06-16 2009-11-19 ノヴァカーディア，インク． うっ血性心不全および急性体液過剰の患者において入院期間を短縮するための方法
JP2016515623A (ja) * 2013-04-05 2016-05-30 エスシーファーマシューティカルズ インコーポレイテッド フロセミドの皮下投与用の医薬製剤
JP2023505189A (ja) * 2019-12-04 2023-02-08 レスク ファーマシューティカルズ エルエルシー 経口利尿薬に不応性の浮腫を処置するための方法及び組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CRYSTENGCOMM, vol. 14, no. 7, JPN6026020063, 2012, pages 2428 - 2434, ISSN: 0005869203 *

Also Published As

Publication number Publication date
EP4351554A4 (en) 2025-05-07
KR20240042402A (ko) 2024-04-02
IL309160A (en) 2024-02-01
US20240285566A1 (en) 2024-08-29
AU2022289724A1 (en) 2024-01-18
EP4351554A1 (en) 2024-04-17
CA3221710A1 (en) 2022-12-15
WO2022261344A8 (en) 2023-02-02
WO2022261344A1 (en) 2022-12-15
CN117915905A (zh) 2024-04-19
BR112023025880A2 (pt) 2024-02-27

Similar Documents

Publication Publication Date Title
US12558330B2 (en) Methods and compositions for treating edema refractory to oral diuretics
JP7048576B2 (ja) 酸素化コレステロールサルフェート、並びにポリアルキレングリコール、カルボキシメチルセルロース、及びポリオキシルグリセリドのうち少なくとも１種を含む組成物
TWI815796B (zh) 包含５－膽甾烯－３，２５－二醇３－硫酸酯（２５ｈｃ３ｓ）或其醫藥上可接受之鹽及至少一種環狀寡醣的組成物，以及使用彼等之方法
EP2849792B1 (en) Liquid formulation
US20120040970A1 (en) Intranasal delivery system for dantrolene
US20210023003A1 (en) Amljodipine formulations
TW201521786A (zh) 胺碘酮類似物（ｂｕｄｉｏｄａｒｏｎｅ）調配物
US20240285566A1 (en) Subcutaneous formulation and methods for treating edema refractory to oral diuretics
ES2396502T3 (es) Formulaciones para la administración terapéutica de la hormona estimulante de la tiroides (TSH)
US20140107130A1 (en) Oral Solution Formulations of Aripiprazole
WO2022217029A1 (en) Compositions and methods for delivering pharmaceutical agents
HK40080175A (en) Methods and compositions for treating edema refractory to oral diuretics
KR20210032437A (ko) 심부전의 치료를 위한 신규한 약제학적 용도
US10201552B2 (en) Method of increasing the bioavailability of an HIV drug
US20250319070A1 (en) Losartan liquid formulations and methods of use
Ichai et al. Sodium disorders
Emmett Fluid and Electrolyte Disturbances
HK1208372B (en) Liquid formulation

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250606

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260526